EULAR 2019 Archives - Medical Conferences

Home > Rheumatology > EULAR 2019

European Congress of Rheumatology

12–15 June 2019 Madrid, Spain

Letter from the Editor

Editor

Prof. Dennis McGonagle, University of Leeds, United Kingdom

Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

Presented By

Dr Roy Fleischmann, University of Texas Southwestern Medical Center, Dallas, USA

Rheumatoid Arthritis

Cohort study shows improvement during 25 years of RA treatment

Presented By

Dr Xanthe Matthijssen, Leiden University Medical Center, the Netherlands

Filgotinib in RA patients with inadequate response or naïve to methotrexate

Presented By

Prof. Rene Westhovens, University Hospital Leuven, Belgium

Clinical effectiveness of fenebrutinib in RA patients with methotrexate or TNFi failure

Presented By

Dr Stanley Cohen, Metroplex Clinical Research Center, Dallas, USA

Peficitinib likely efficacious and safe

Short methotrexate stop is safe in patients with RA

Presented By

Dr Min Jung Kim, Seoul National University Hospital, South Korea

Tofacitinib is safe according to real-world data analysis

Presented By

Dr Joel Kremer, Albany Medical College, New York, USA

Switching upadacitinib and adalimumab is beneficial in refractory RA

Tapering of prednisone in RA patients who achieved low disease activity or remission with tocilizumab

Presented By

Prof. Gerd Burmester, Free University and Humboldt University of Berlin, Germany

Efficacy and safety of E6011 in RA patients with inadequate response to methotrexate

Presented By

Dr Yoshiya Tanaka, University of Occupational and Environmental Health, Japan

Preliminary efficacy and safety data of RG6125 in RA patients with an inadequate response to TNF inhibitors

Presented By

Uwe Junker, Roche Innovation Center Basel, Switzerland

Integrated 10-year analysis confirms safety profile abatacept

Presented By

Dr Teresa Simon, Bristol-Myers Squibb, USA

Switching among multiple infliximab biosimilars does not cause immunogenicity

Presented By

Dr Jéróme Avouac, Paris Descartes University, France

Switch to sarilumab from adalimumab is efficacious and safe

Presented By

Dr Gerd Burmester, Free University and Humboldt University of Berlin, Germany

Axial Spondyloarthritis

Treat-to-target approach emerging in axial spondyloarthritis

Presented By

Dr Pedro Machado, University College London Hospitals, United Kingdom

NSAIDs consumption is linked to patient-assessed disease activity and decreases with use of TNF inhibitors

Presented By

Dr Olafur Palsson, University Hospital Reykjavik, Iceland

Psoriatic Arthritis

Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

Presented By

Dr Roy Fleischmann, University of Texas Southwestern Medical Center, Dallas, USA

Efficacy and safety of bimekizumab in patients with active PsA

Presented By

Dr Christopher Ritchlin, University of Rochester Medical Centre, USA

Filgotinib is efficacious and safe in PsA

Presented By

Prof. Philip Mease, Swedish Medical Center and University of Washington, Seattle, USA

Ixekizumab improves signs and symptoms in TNFi-naïve PsA patients

Presented By

Dr Amanda Gellett, Eli Lilly, USA

Etanercept and methotrexate as first-line treatment in PsA

Presented By

Prof. Philip Mease, University of Washington, USA

Unacceptable pain is common in patients with psoriatic arthritis

Presented By

Dr Tor Olofsson, Lund University, Sweden

Osteoarthritis and Osteoporosis

What is new in osteoarthritis

Presented By

Prof. Francis Berenbaum, Sorbonne Université, France

How to treat osteoporosis

Presented By

Prof. Serge Ferrari, Geneva University Hospital, Switzerland

Miscellaneous

Interstitial lung disease in rheumatic diseases and systemic sclerosis

Presented By

Dr Jan Grutters, University Medical Center Utrecht, the Netherlands

Emapalumab in patients with macrophage activation syndrome

Presented By

Dr Fabrizio De Benedetti, Ospedale Pediatrico Bambino Gesù, Italy

Support for tocilizumab use in giant cell arteritis

Presented By

Dr John Stone, Massachusetts General Hospital, Boston, USA

Medical Conferences

EULAR 2019

Table of Contents

Featured articles

Letter from the Editor

Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

Rheumatoid Arthritis

Cohort study shows improvement during 25 years of RA treatment

Filgotinib in RA patients with inadequate response or naïve to methotrexate

Clinical effectiveness of fenebrutinib in RA patients with methotrexate or TNFi failure

Peficitinib likely efficacious and safe

Short methotrexate stop is safe in patients with RA

Tofacitinib is safe according to real-world data analysis

Switching upadacitinib and adalimumab is beneficial in refractory RA

Tapering of prednisone in RA patients who achieved low disease activity or remission with tocilizumab

Efficacy and safety of E6011 in RA patients with inadequate response to methotrexate

Preliminary efficacy and safety data of RG6125 in RA patients with an inadequate response to TNF inhibitors

Integrated 10-year analysis confirms safety profile abatacept

Switching among multiple infliximab biosimilars does not cause immunogenicity

Switch to sarilumab from adalimumab is efficacious and safe

Axial Spondyloarthritis

Treat-to-target approach emerging in axial spondyloarthritis

NSAIDs consumption is linked to patient-assessed disease activity and decreases with use of TNF inhibitors

Psoriatic Arthritis

Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

Efficacy and safety of bimekizumab in patients with active PsA

Filgotinib is efficacious and safe in PsA

Ixekizumab improves signs and symptoms in TNFi-naïve PsA patients

Etanercept and methotrexate as first-line treatment in PsA

Unacceptable pain is common in patients with psoriatic arthritis

Osteoarthritis and Osteoporosis

What is new in osteoarthritis

How to treat osteoporosis

Miscellaneous

Interstitial lung disease in rheumatic diseases and systemic sclerosis

Emapalumab in patients with macrophage activation syndrome

Support for tocilizumab use in giant cell arteritis